Staňte se členy

Odkazy a zdroje - Studie - GREACE



GREACE

Greek Atorvastatin and Coronary-heart-disease Evaluation

Author(s)
Athyros VG, Papageorgiou AA, Mercouris BR, Athyrou VV, Symeonidis AN, Basayannis EO, Demitriadis DS, Kontopoulos AG

Title(s)
Treatment with atorvastatin to the National Cholesterol Educational Program goal versus ‘usual’ care in secondary coronary heart disease prevention

Reference(s)
Curr Med Res Opin 2002;18:220-8

Disease
Coronary heart disease

Purpose
To assess the effect of atorvastatin on mortality and morbidity in patients with coronary heart disease

Study design
Randomised, open

Follow-up
3 years

Patients
1600 patients (800 atorvastatin, 800 usual care), aged < 75 years, with prior MI or > 70% stenosis of at least one coronary artery, LDL cholesterol > 100 mg/dl and triglycerides < 400 mg/dl

Treatment regimen
Atorvastatin, 10-80 mg/day, titrated to LDL cholesterol < 100 mg/dl, or usual care

Concomitant therapy
-

Results
Total mortality was 2.9% with atorvastatin and 5% with usual care (p = 0.0021). Similar reductions with atorvastatin compared to usual care were seen in coronary mortality (relative risk 0.53; p = 0.0017) and coronary morbidity (relative risk 0.46; p < 0.0001)
– Plehn JF, Circulation 1999;99:216–23